Ceribell Q3 loss misses estimates; raises 2026 revenue guidance
CBLL•Ceribell reported third-quarter revenue of $29.30 million, up 30% year over year and slightly above estimates, while its $0.55 loss per share missed expectations. The company raised its 2026 revenue guidance to $115 million-$117 million.
1. Quarterly results
Ceribell's third-quarter revenue rose 30% year over year to $29.30 million, compared with analyst estimates of $29.16 million. Its loss per share widened to $0.55, missing the $0.51 estimate, and net loss was $21.40 million versus an estimate of $19.72 million.
2. Guidance and growth
Ceribell raised its 2026 revenue guidance to $115 million-$117 million and said the outlook excludes material contributions from its neonate, pediatric and delirium products. The company said growth was driven by record new customer additions, higher utilization and increased adoption within existing accounts. Operating expenses rose 36% to $46.9 million, while higher gross margin reflected manufacturing cost reductions and a new manufacturing line in Vietnam.
